Vitamin D status and cholecalciferol supplementation on patients with active Basedow disease: a clinical study

Eugeniya Nedeltcheva-Petrova^{1, 2}, Mircea Ghemigian³, Boris Petrov⁴, Adina Ghemigian^{1, 2}, Mara Carsote^{1, 2}, Florica Șandru^{5, 6}, Ruxandra D. Sinescu-Bălțăteanu^{7, 8}, Alexandru Filipescu^{9, 10}, Mihai C. Dumitrașcu^{9, 11}

1 - Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
2 - Department of Endocrinology, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania
3 - Department of Endocrine Surgery, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania
4 - Department of Gastroenterology, Medica Endoprovision Clinique, Bucharest, Romania
5 - Department of Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
6 - Department of Dermatology, Elias Emergency Hospital, Bucharest, Romania
7 - Department of Plastic and Reconstructive Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
8 - Department of Plastic and Reconstructive Surgery, Elias Emergency Hospital, Bucharest, Romania
9 - Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
10 - Department of Obstetrics and Gynaecology, Elias Emergency Hospital, Bucharest, Romania
11 - Department of Obstetrics and Gynecology, University Emergency Hospital, Bucharest, Romania

Correspondence: Mara Carsote

Received: September 4, 2021

Accepted: December 16, 2021

Abstract:

This study aims to analyze the 25-hydroxyvitamin D (25OHD) corelations with TRab (anti-TSH receptor Antibodies) at baseline and after corections of 25OHD deficit. Method: Prospective, interventional, controled, single-centre, clinical study on 62 patients with active Basedow disease (BD), admitted at C.I. Parhon National Institute of Endocrinology, Bucharest, Romania, between 2013 and 2020. Patients were divided into two groups: one group (N=37) received 2000 IU of daily cholecalciferol and a second one (N=25) without vitamin D supplementation, all subjects being under anti-thyroid drugs (standard guideline therapy). 25OHD and TRab levels were assessed at start and after 6, respective 12 months. Results: Initial evaluation confirmed vitamin D deficiency (mean 25OHD of 18.33±6.45 ng/mL). At start, TRab negatively correlates with 25OHD (N=62, r= -0.22, p=0.08). The decrease in TRab was statistically significant higher in group 1 versus group 2 after 6 months (35.84% versus 3.53%, p=0.03). After 12 months, TRab decreased with 56.28% in group 1, respective 27.16% in group 2 (p=0.03). In group 1, inverse correlation between 25OHD and TRab was consistent at 6 and 12 months. Conclusion: In patients with active BD, TRab values were negatively correlated with 25OHD at baseline and during follow-up. Correction of vitamin D deficiency is correlated with the decrease of TRab levels.